Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Matrixx reports lowest cold season since 1999

This article was originally published in The Tan Sheet

Executive Summary

Phoenix-based Matrixx Initiatives announced Jan. 16 the incidence of illness for the 2007/2008 season, which runs October to March, has hit the lowest level since its Zicam cough/cold brand was introduced in 1999, which affected reorders the firm received in the third quarter ended Dec. 31, 2007 ("The Tan Sheet" Oct. 29, 2007, In Brief). Matrixx anticipates sales for the quarter to fall below $36.2 million and a net loss "on par" with $463,000, as recorded in the quarter ended Dec. 31, 2006. The firm will update the previously issued guidance for fiscal 2008, but says its most recent tracking data shows an increase in illness and if it continues, it anticipates its fiscal 2008 net sales to be at 5 percent or above the $97.6 million recorded at the end of fiscal 2007. The firm expects to report net income between $9 million and $10 million, or $.90 and $1.00 per share...

You may also be interested in...



Matrixx net sales down

Sales of Zicam cough/cold products increased about 15% in Matrixx Initiatives' second quarter, the firm reports Oct. 24. Marketing spending for the 2007/2008 cold season will increase 15%, the company projects. However, net sales in the July-September period for the Phoenix-based OTC healthcare firm fell 16% to $28.6 mil. and net income declined 10.4% to $6.4 mil. In a same-day earnings call, Matrixx executives said the firm's performance is in line with expectations due to large retail customers' caution in off-season purchases of cough/cold products...

J&J To Power Ahead With 10 Launches In Four Years

 Johnson & Johnson has achieved exceptional growth in recent years, and a raft of new products is set to sustain it further. 

Bayer's Efforts To Pioneer Tumor-Agnostic Market In Europe Held Back

Bayer’s drive to lead a new market opportunity in Europe for histology-independent cancer agents like Vitrakvi has been set back by interim decisions from the UK’s NICE and Germany’s IQWiG, but there is a now a clear pathway to follow.

 

Topics

UsernamePublicRestriction

Register

PS101279

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel